Related Experiment Video
Updated: Sep 22, 2025

Author Spotlight: Repetitive Transcranial Magnetic Stimulation Combined with Movement Observation in Cerebral Palsy
Published on: August 9, 2024
Spasticity management and resolution of paroxysmal sympathetic hyperactivity in the acute care setting: a case series
Arline Edmond1, Ondrea McKay1, Natasha Mehta2
1Department of Physical Medicine and Rehabilitation, Rutgers-New Jersey Medical School, Newark, NewJersey, USA.
Objective:
The aim is to highlight three cases of focal spasticity and/or dystonia as potential noxious triggers and treatment targets of Paroxysmal Sympathetic Hyperactivity (PSH).
Methods:
We review the literature, explore pathophysiology, and review treatment options. We discuss the clinical course and management of three unique patients who presented to a teaching hospital with severe traumatic brain injury (TBI) complicated by PSH managed by a physiatry consult team.
Results:
Three patients, ranging in age from 8 months to 27 years, were admitted with severe TBI complicated by PSH refractory to pharmacologic management. All three patients, however, had resolution of PSH within 24-72 hours of focal spasticity treatments (i.e. casting and botulinum toxin injections).
Conclusion:
PSH is a constellation of physiologic findings and physical symptoms that is incompletely understood. Management is based on addressing predominant symptom features and physiologic responses. In certain cases, ongoing spasticity and/or dystonia may serve as noxious stimuli for persistence of PSH in moderate to severe brain injury. As such, the focal treatment of spasticity and/or dystonia may be considered as a treatment target in the management of refractory PSH.
Related Concept Videos
Skeletal Muscle Relaxants: Therapeutic Uses
Acute Coronary Syndrome V: Nursing Management
Pleural Effusion II: Symptoms and Management
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
Peripherally and Centrally Acting Muscle Relaxants: A Comparison
Centrally acting muscle relaxants can be further divided into spasmolytic and antispasmodic drugs. Spasmolytic...
Classification of Skeletal Muscle Relaxants
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
Acute Respiratory Failure-V
Ensure that patients are monitored continuously for their response to therapy, including changes in...

